Oral doxifluridine in advanced hepatocellular carcinoma

A phase II study

Monica Lencioni, Alfredo Falcone, Giacomo Allegrini, Elisabetta Pfanner, Gianluca Masi, Isa Brunetti, Roberta Di Marsico, Eloise Fontana, Cinzia Orlandini, Corrado Gallo Stampino, Carlo Bartolozzi, Pier Franco Conte

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish
Pages (from-to)204-209
Number of pages6
JournalOncology
Volume59
Issue number3
Publication statusPublished - 2000

Fingerprint

Hepatocellular Carcinoma
Diarrhea
Uridine Phosphorylase
Stomatitis
Fluorouracil
Nausea
Vomiting
Appointments and Schedules
doxifluridine
Confidence Intervals
Neoplasms

Keywords

  • Doxifluridine
  • Hepatocellular carcinoma
  • Oral chemotherapy
  • Phase II study

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Lencioni, M., Falcone, A., Allegrini, G., Pfanner, E., Masi, G., Brunetti, I., ... Conte, P. F. (2000). Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. Oncology, 59(3), 204-209.

Oral doxifluridine in advanced hepatocellular carcinoma : A phase II study. / Lencioni, Monica; Falcone, Alfredo; Allegrini, Giacomo; Pfanner, Elisabetta; Masi, Gianluca; Brunetti, Isa; Di Marsico, Roberta; Fontana, Eloise; Orlandini, Cinzia; Stampino, Corrado Gallo; Bartolozzi, Carlo; Conte, Pier Franco.

In: Oncology, Vol. 59, No. 3, 2000, p. 204-209.

Research output: Contribution to journalArticle

Lencioni, M, Falcone, A, Allegrini, G, Pfanner, E, Masi, G, Brunetti, I, Di Marsico, R, Fontana, E, Orlandini, C, Stampino, CG, Bartolozzi, C & Conte, PF 2000, 'Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study', Oncology, vol. 59, no. 3, pp. 204-209.
Lencioni M, Falcone A, Allegrini G, Pfanner E, Masi G, Brunetti I et al. Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study. Oncology. 2000;59(3):204-209.
Lencioni, Monica ; Falcone, Alfredo ; Allegrini, Giacomo ; Pfanner, Elisabetta ; Masi, Gianluca ; Brunetti, Isa ; Di Marsico, Roberta ; Fontana, Eloise ; Orlandini, Cinzia ; Stampino, Corrado Gallo ; Bartolozzi, Carlo ; Conte, Pier Franco. / Oral doxifluridine in advanced hepatocellular carcinoma : A phase II study. In: Oncology. 2000 ; Vol. 59, No. 3. pp. 204-209.
@article{885850bfda2049c29e786c81b1862968,
title = "Oral doxifluridine in advanced hepatocellular carcinoma: A phase II study",
abstract = "Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16{\%}) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17{\%}, 95{\%} confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.",
keywords = "Doxifluridine, Hepatocellular carcinoma, Oral chemotherapy, Phase II study",
author = "Monica Lencioni and Alfredo Falcone and Giacomo Allegrini and Elisabetta Pfanner and Gianluca Masi and Isa Brunetti and {Di Marsico}, Roberta and Eloise Fontana and Cinzia Orlandini and Stampino, {Corrado Gallo} and Carlo Bartolozzi and Conte, {Pier Franco}",
year = "2000",
language = "English",
volume = "59",
pages = "204--209",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Oral doxifluridine in advanced hepatocellular carcinoma

T2 - A phase II study

AU - Lencioni, Monica

AU - Falcone, Alfredo

AU - Allegrini, Giacomo

AU - Pfanner, Elisabetta

AU - Masi, Gianluca

AU - Brunetti, Isa

AU - Di Marsico, Roberta

AU - Fontana, Eloise

AU - Orlandini, Cinzia

AU - Stampino, Corrado Gallo

AU - Bartolozzi, Carlo

AU - Conte, Pier Franco

PY - 2000

Y1 - 2000

N2 - Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.

AB - Hepatocellular carcinoma (HCC) remains one of the most common neoplasms in the world. Doxifluridine is an oral fluoropyrimidine derivative activated to 5-fluorouracil by uridine phosphorylase which is more expressed in malignant cells. Therefore, we conducted a phase II study to evaluate the activity of oral doxifluridine in patients with advanced hepatocellular carcinoma. Twenty-five advanced hepatocellular carcinoma patients entered the study; doxifluridine was given orally at the initial daily total dose of 2,250 mg for 4 consecutive days every week. All patients are evaluable for toxicity: these included mainly grade 1-2 (WHO) diarrhea, stomatitis, nausea and vomiting; 4 patients (16%) experienced grade 3-4 diarrhea. Twenty-four patients are evaluable for response and 1 complete and 3 partial responses have been observed (response rat 17%, 95% confidence interval: 5-37). Oral doxifluridine at the dose and schedule we used, although having only modest activity in advanced HCC, may represent an alternative to other frequently used chemotherapeutic agents, because of its favorable toxicity profile and its simple route of administration. Copyright (C) 2000 S. Karger AG, Basel.

KW - Doxifluridine

KW - Hepatocellular carcinoma

KW - Oral chemotherapy

KW - Phase II study

UR - http://www.scopus.com/inward/record.url?scp=0033764698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033764698&partnerID=8YFLogxK

M3 - Article

VL - 59

SP - 204

EP - 209

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 3

ER -